J
Jonathan D. Adachi
Researcher at McMaster University
Publications - 606
Citations - 35172
Jonathan D. Adachi is an academic researcher from McMaster University. The author has contributed to research in topics: Osteoporosis & Bone density. The author has an hindex of 96, co-authored 589 publications receiving 31641 citations. Previous affiliations of Jonathan D. Adachi include St. Joseph's Healthcare Hamilton & University of Saskatchewan.
Papers
More filters
Journal ArticleDOI
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles,Cathleen S. Colón-Emeric,Jay Magaziner,Jonathan D. Adachi,Carl F. Pieper,Carlos Mautalen,Lars Hyldstrup,Chris Recknor,Lars Nordsletten,Kathy A. Moore,Catherine Lavecchia,Jie Zhang,Peter Mesenbrink,Patricia K. Hodgson,Ken Abrams,John J. Orloff,Zebulun D. Horowitz,Erik Fink Eriksen,Steven Boonen +18 more
TL;DR: An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival.
Journal ArticleDOI
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
Felicia Cosman,Daria B. Crittenden,Jonathan D. Adachi,Neil Binkley,Edward Czerwiński,Serge Ferrari,Lorenz C. Hofbauer,E. Lau,E. M. Lewiecki,Akimitsu Miyauchi,C. A. F. Zerbini,C. E. Milmont,L. Chen,Judy Maddox,Paul D Meisner,Cesar Libanati,Andreas Grauer +16 more
TL;DR: In postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months.
Journal Article
Canadian normative data for the SF-36 health survey
Wilma M. Hopman,Tanveer Towheed,Tassos Anastassiades,Alan Tenenhouse,Suzette Poliquin,Claudie Berger,Lawrence Joseph,Jacques P. Brown,Timothy M. Murray,Jonathan D. Adachi,David A. Hanley,Emmanuel A. Papadimitropoulos +11 more
TL;DR: Canadian men scored substantially higher than women on all 8 domains and the 2 summary component scales of the SF-36 and scored higher than their UK counterparts on 4 domains, although many of the differences are not large.
Journal ArticleDOI
Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
Jonathan D. Adachi,William G. Bensen,Jacques P. Brown,David A. Hanley,Anthony B. Hodsman,Robert G. Josse,David L. Kendler,Brian C. Lentle,Wojciech P. Olszynski,Louis-Georges Ste-Marie,Alan Tenenhouse,Chines Arkadi Aaron +11 more
TL;DR: Intermittent etidronate therapy prevents the loss of vertebral and trochanteric bone in corticosteroid-treated patients.
Journal ArticleDOI
Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial
Pierre D. Delmas,Kristine E. Ensrud,Jonathan D. Adachi,Kristine D. Harper,S Sarkar,Carlo Gennari,Jean-Yves Reginster,Huibert A.P. Pols,Robert R. Recker,Steven T. Harris,W Wu,Harry K. Genant,Dennis M. Black,Richard Eastell +13 more
TL;DR: Raloxifene 60 and 120 mg/d through 4 yr decreased the cumulative risk of new vertebral fractures in postmenopausal women with osteoporosis.